OOIR: Observatory of International Research

Papers

(The median citation count of Pharmacogenomics Journal is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data	55
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data	41
Economic evaluation in psychiatric pharmacogenomics: a systematic review	35
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs	30
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy	22
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study	21
Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis	20
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience	18
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection	18
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle	17
Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan	16
Does the RAAS play a role in loss of taste and smell during COVID-19 infections?	15
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review	14
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States	14
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders	13
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis	13
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review	12
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model	11
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis	10
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel	10
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore	10
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer	10
The variants at FLNA and FLNB contribute to the susceptibility of hypertension and stroke with differentially expressed mRNA	10
The clinically relevant CYP2C83 and CYP2C92 haplotype is inherited from Neandertals	10
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19	9

Using ChatGPT to predict the future of personalized medicine	9
CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice	9
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors	9
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment	8
Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients	8
Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder	8
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers	7
New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin	7
HLA-B07:02 and HLA-C07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure	7
A review of the existing literature on buprenorphine pharmacogenomics	7
Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes	7
Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients	7
Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis	7
A blockchain-based framework to support pharmacogenetic data sharing	7
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?	6
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial	6
Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study	6
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges	6
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data	6
Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity	6
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder	6
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis	6
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?	5
The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens	5
Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder	5
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease	5
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer	5
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care	5
Clinical utility of pharmacogenetics in a psychiatric and primary care population	5
Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota	5
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study	5
Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients	5
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder	5
Gene expression signatures predict response to therapy with growth hormone	5
Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients	4
Pharmacogenomic analysis of a genetically distinct Indigenous population	4
A survey of cancer genome signatures identifies genes connected to distinct chromosomal instability phenotypes	4
Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms	4
Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study	4
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder	4
Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women	4
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population	4
Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling	4
Whole-genome sequencing analysis of clozapine-induced myocarditis	3
A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions	3
Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes	3
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach	3
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort	3
Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations	3
A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL−1 at the time of loss of consciousness	3

Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors	3
Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome	3
Point of care CYP2C19 genotyping after percutaneous coronary intervention	3
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study	3
Identification of a sex-stratified genetic algorithm for opioid addiction risk	3